Senior Vice President and Chief Commercial Officer · BIOCRYST PHARMACEUTICALS INC (BCRX)

Lynne Powell

A named executive officer of BIOCRYST PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,528,624

Salary $382,454Stock awards $0

FY2017: $1,487,087

5th of 5 named executive officers at Biocryst Pharmaceuticals by FY2018 total.

5 named officers on file for BIOCRYST PHARMACEUTICALS, FY2018

Lynne Powell’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • BCRX’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BIOCRYST PHARMACEUTICALS’s whole pay program stands against its peers

  • BIOCRYST PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BCRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 17, 2019 (DEF 14A).

Free

Get Lynne Powell’s full pay file as a PDF — free

More than this page: up to 10 years of Lynne’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Lynne Powell compensation by year

BIOCRYST PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as BIOCRYST PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$360,500$369,513$382,454
Bonus$0$122,570$0
Stock awards$0$0$0
Option awards$282,798$838,543$922,640
Non-equity incentive$0$111,395$164,455
Pension and deferred compensation$0$0$0
All other$29,641$45,066$59,075
Total$672,939$1,487,087$1,528,624

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOCRYST PHARMACEUTICALS INC DEF 14A filed April 17, 2019, accession 0001171843-19-002458, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BIOCRYST PHARMACEUTICALS INC filed document, accession 0001171843-19-002458. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2019.

$673K
$1.5M
$1.5M
FY16
FY17
FY18
SalaryBonusNon-equity incentiveOption awardsAll other

BIOCRYST PHARMACEUTICALS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Jon StonehousePresident, Chief Executive Officer and Director$4,167,643
MBBS William P. SheridanChief Medical Officer$2,349,219
Thomas StaabSenior Vice President and Chief Financial Officer$1,797,270
Yarlagadda BabuSenior Vice President of Drug Discovery$1,755,510
Lynne Powell · this pageSenior Vice President and Chief Commercial Officer$1,528,624

The full BIOCRYST PHARMACEUTICALS compensation record

free company brief

This page is one person within BIOCRYST PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the BIOCRYST PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOCRYST PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lynne Powell's compensation dossier · One-time report. No refunds.